CMPSHIGH SIGNALFINANCIAL10-K

CMPS reported substantially higher net losses and deteriorating operating cash flow burn as this clinical-stage biotech continues advancing its psilocybin treatment development.

The company's financial burn rate has accelerated meaningfully, with net losses growing substantially and operating cash outflows increasing by roughly one-third year-over-year. For a pre-revenue biotech company, this level of cash burn acceleration raises important questions about runway duration and future funding needs, especially given management's explicit warnings about needing additional financing.

Comparing 2026-03-24 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

CMPS experienced a significant deterioration in its financial position, with net losses growing substantially while operating cash outflows increased by approximately 32%. The company's cash burn has accelerated notably across both metrics, reflecting the expensive nature of advancing clinical trials for their COMP360 psilocybin treatment. This financial trajectory is concerning for a pre-revenue company that explicitly states it expects continued losses and will require additional funding to sustain operations.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-85.6%
-$155.1M→-$287.9M

Net income declined 85.6% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-31.9%
-$119.2M→-$157.2M

Operating cash flow fell 31.9% — earnings quality concerns; investigate working capital changes and non-cash items.

LANGUAGE CHANGES
NEW — 2026-03-24
PRIOR — 2025-02-27
ADDED
Dollar), the risk of an economic slowdown or recession in the U.S., instability in the banking system, overall market volatility in the U.S.
or the UK, including as a result of, among other factors, geopolitical conflict (such as, the war between Russia and Ukraine and conflict in the Middle East), international tensions or instability (including from the effects of announced or future tariff increases), significant changes in U.S.
References to we, our, us and the Company refer to Compass Pathways plc.
We expect to incur losses for the foreseeable future and may never achieve or maintain profitability; Unless and until we generate product revenue and achieve and sustain profitability, we will continue to need additional financing to fund our operations and capital expenditures.
If we are unable to do so, our commercialization prospects would be limited and our business would be harmed; In our clinical trials, we currently rely on specially trained, licensed healthcare professionals working at third-party clinical trial sites and upon regulatory approval we expect to continue to rely on healthcare professionals working at third-party sites, to monitor and safeguard participants during administration of our COMP360 psilocybin treatment.
+7 more — sign up free →
REMOVED
Dollar, the risk of economic slowdown or recession in the U.S., instability in the banking system, overall market volatility in the U.S.
or the UK, including as a result of, among other factors, the ongoing war between Russia and Ukraine, conflict in the Middle East, the potential for significant changes in U.S.
We expect to incur losses for the foreseeable future and may never achieve or maintain profitability; We will need substantial additional funding to complete the development and commercialization of our investigational COMP360 psilocybin treatment.
Our outstanding warrants may not be exercised for cash before such warrants expire and we may not receive any additional proceeds from such warrants.
Our ability to raise additional funds may be adversely impacted by macroeconomic conditions, changing regulatory conditions, and disruptions to and volatility in the credit and financial markets in the U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →